Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001213900-25-043374
Filing Date
2025-05-14
Accepted
2025-05-14 16:35:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS SUPPLEMENT ea0241505-424b3_oruka.htm 424B3 884166
2 GRAPHIC image_001.jpg GRAPHIC 5378
  Complete submission text file 0001213900-25-043374.txt   893012
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-283212 | Film No.: 25946426
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)